Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus ipilimumab or nivolumab plus chemotherapy versus standard chemotherapy in untreated unresectable or metastatic urothelial cancer
2016-003881-14Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in transitional cell carcinoma (TCC) (3 arms), sponsored by Bristol Myers Squibb. Started Feb 2017; status: active.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2016-003881-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003881-14.